E2F1 and cancer: In this regard, our previous studies demonstrated that CTL-mediated immune selection enriches immune-refractory cancer cells with CSC-like properties and resistance to CTL-mediated apoptosis, driven by E2F1 through FGFR signaling or NANOG induction.